P
TAK icon

&Partners’s Takeda Pharmaceutical TAK Stock Holding History

&Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$613K Buy
33,099
+4,470
+16% +$78.5K ﹤0.01% 1585
2025
Q4 		$446K Buy
28,629
+2,554
+10% +$36.5K ﹤0.01% 1679
2025
Q3 		$382K Buy
26,075
+4,877
+23% +$72.4K ﹤0.01% 1621
2025
Q2 		$331K Buy
21,198
+2,749
+15% +$40.6K ﹤0.01% 1571
2025
Q1 		$278K Sell
18,449
-5,353
-22% -$75K ﹤0.01% 1444
2024
Q4 		$317K Buy
23,802
+7,055
+42% +$96.9K ﹤0.01% 1307
2024
Q3 		$238K Buy
16,747
+5,351
+47% +$75.9K ﹤0.01% 1217
2024
Q2 		$147K Buy
11,396
+319
+3% +$4.22K 0.01% 866
2024
Q1 		$154K Buy
+11,077
New +$161K 0.02% 467

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return